8GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
9Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
10Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
6Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease[J]. N Engl J Med,2008,359(22) :2355- 2365.
7Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases [ J]. Biochimie, 2012,94 ( 10 ) :2180 - 2189.
8Krommidas G, Kostikas K, Papatheodorou G, et al. Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers [ J ]. Respir Med, 2010,104(1) : 40-46.
9Papala M, Kerenidi N, Gourgoniianis KI. Everyday clinical practice and its retlationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD[ J]. Prim Care Respir J, 2013,22(3) : 362 - 364.
